Literature DB >> 29855470

ADAR1-mediated regulation of melanoma invasion.

Yael Nemlich1, Erez Nissim Baruch1,2, Michal Judith Besser1,2, Einav Shoshan3, Menashe Bar-Eli3, Liat Anafi4, Iris Barshack4, Jacob Schachter1, Rona Ortenberg1, Gal Markel5,6,7.   

Abstract

Melanoma cells use different migratory strategies to exit the primary tumor mass and invade surrounding and subsequently distant tissues. We reported previously that ADAR1 expression is downregulated in metastatic melanoma, thereby facilitating proliferation. Here we show that ADAR1 silencing enhances melanoma cell invasiveness and ITGB3 expression. The enhanced invasion is reversed when ITGB3 is blocked with antibodies. Re-expression of wild-type or catalytically inactive ADAR1 establishes this mechanism as independent of RNA editing. We demonstrate that ADAR1 controls ITGB3 expression both at the post-transcriptional and transcriptional levels, via miR-22 and PAX6 transcription factor, respectively. These are proven here as direct regulators of ITGB3 expression. miR-22 expression is controlled by ADAR1 via FOXD1 transcription factor. Clinical relevance is demonstrated in patient-paired progression tissue microarray using immunohistochemistry. The novel ADAR1-dependent and RNA-editing-independent regulation of invasion, mediated by ITGB3, strongly points to a central involvement of ADAR1 in cancer progression and metastasis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29855470      PMCID: PMC5981216          DOI: 10.1038/s41467-018-04600-2

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  68 in total

1.  MiR-320a down-regulation mediates bladder carcinoma invasion by targeting ITGB3.

Authors:  Chao Shang; Hui Zhang; Yan Guo; Yang Hong; Yunhui Liu; Yixue Xue
Journal:  Mol Biol Rep       Date:  2014-01-18       Impact factor: 2.316

2.  Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment.

Authors:  Nuzhat Ahmed; Clyde Riley; Greg Rice; Michael Quinn
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

3.  Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells.

Authors:  F Yu; H Deng; H Yao; Q Liu; F Su; E Song
Journal:  Oncogene       Date:  2010-05-24       Impact factor: 9.867

4.  MiR-185 acts as a tumor suppressor by targeting AKT1 in non-small cell lung cancer cells.

Authors:  Shuai Li; Yulian Ma; Xinfang Hou; Ying Liu; Ke Li; Shuning Xu; Jufeng Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

5.  Adenosine deaminase ADAR1 increases gene expression at the translational level by decreasing protein kinase PKR-dependent eIF-2alpha phosphorylation.

Authors:  Ying Wang; Charles E Samuel
Journal:  J Mol Biol       Date:  2009-09-03       Impact factor: 5.469

6.  Regulation of cancer aggressive features in melanoma cells by microRNAs.

Authors:  Eyal Greenberg; Liat Hershkovitz; Orit Itzhaki; Steven Hajdu; Yael Nemlich; Rona Ortenberg; Nir Gefen; Liat Edry; Shira Modai; Yona Keisari; Michal J Besser; Jacob Schachter; Noam Shomron; Gal Markel
Journal:  PLoS One       Date:  2011-04-25       Impact factor: 3.240

7.  Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis.

Authors:  Einav Shoshan; Aaron K Mobley; Russell R Braeuer; Takafumi Kamiya; Li Huang; Mayra E Vasquez; Ahmad Salameh; Ho Jeong Lee; Sun Jin Kim; Cristina Ivan; Guermarie Velazquez-Torres; Ka Ming Nip; Kelsey Zhu; Denise Brooks; Steven J M Jones; Inanc Birol; Maribel Mosqueda; Yu-ye Wen; Agda Karina Eterovic; Anil K Sood; Patrick Hwu; Jeffrey E Gershenwald; A Gordon Robertson; George A Calin; Gal Markel; Isaiah J Fidler; Menashe Bar-Eli
Journal:  Nat Cell Biol       Date:  2015-02-16       Impact factor: 28.824

8.  Features of mammalian microRNA promoters emerge from polymerase II chromatin immunoprecipitation data.

Authors:  David L Corcoran; Kusum V Pandit; Ben Gordon; Arindam Bhattacharjee; Naftali Kaminski; Panayiotis V Benos
Journal:  PLoS One       Date:  2009-04-23       Impact factor: 3.240

Review 9.  Emerging molecular targets in melanoma invasion and metastasis.

Authors:  Jose L Orgaz; Victoria Sanz-Moreno
Journal:  Pigment Cell Melanoma Res       Date:  2012-11-21       Impact factor: 4.693

10.  CDK11p58 inhibits ERα-positive breast cancer invasion by targeting integrin β3 via the repression of ERα signaling.

Authors:  Yayun Chi; Sheng Huang; Lei Wang; Ruoji Zhou; Lisha Wang; Xiuying Xiao; Dali Li; Ying Cai; Xiaoyan Zhou; Jiong Wu
Journal:  BMC Cancer       Date:  2014-08-08       Impact factor: 4.430

View more
  16 in total

Review 1.  Adenosine deaminase acting on RNA (ADAR1), a suppressor of double-stranded RNA-triggered innate immune responses.

Authors:  Charles E Samuel
Journal:  J Biol Chem       Date:  2019-02-01       Impact factor: 5.157

2.  Unbiased Identification of trans Regulators of ADAR and A-to-I RNA Editing.

Authors:  Emily C Freund; Anne L Sapiro; Qin Li; Sandra Linder; James J Moresco; John R Yates; Jin Billy Li
Journal:  Cell Rep       Date:  2020-05-19       Impact factor: 9.423

3.  Mass spectrometry-based proteomic capture of proteins bound to the MACC1 promoter in colon cancer.

Authors:  Yahui Huang; Yi Xiang; Zhongpeng Xie; Yuxiang Cai; Qiongzhi Yang; Huichao Huang; Zhuchu Chen; Zhefeng Xiao; Qiongqiong He
Journal:  Clin Exp Metastasis       Date:  2020-07-01       Impact factor: 5.150

4.  Glycan Epitope and Integrin Expression Dynamics Characterize Neural Crest Epithelial-to-Mesenchymal Transition (EMT) in Human Pluripotent Stem Cell Differentiation.

Authors:  Ria Thomas; Vishal Menon; Rakesh Mani; Jan Pruszak
Journal:  Stem Cell Rev Rep       Date:  2022-06-21       Impact factor: 5.739

5.  The E3 ubiquitin ligase SMURF2 stabilizes RNA editase ADAR1p110 and promotes its adenosine-to-inosine (A-to-I) editing function.

Authors:  Praveen Koganti; Venkata Narasimha Kadali; Dhanoop Manikoth Ayyathan; Andrea Emanuelli; Biagio Paolini; Gal Levy-Cohen; Michael Blank
Journal:  Cell Mol Life Sci       Date:  2022-04-11       Impact factor: 9.261

Review 6.  ADAR1 and its implications in cancer development and treatment.

Authors:  Allison R Baker; Frank J Slack
Journal:  Trends Genet       Date:  2022-04-19       Impact factor: 11.821

7.  Integrin α5 promotes migration and invasion through the FAK/STAT3/AKT signaling pathway in icotinib-resistant non-small cell lung cancer cells.

Authors:  Yang Yang; Yizhe Wang; Xiaofang Che; Kezuo Hou; Jie Wu; Chunlei Zheng; Yang Cheng; Yunpeng Liu; Xuejun Hu; Jingdong Zhang
Journal:  Oncol Lett       Date:  2021-05-24       Impact factor: 2.967

8.  IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification.

Authors:  Phaik Ju Teoh; Tae-Hoon Chung; Pamela Y Z Chng; Sabrina H M Toh; Wee Joo Chng
Journal:  Haematologica       Date:  2019-08-14       Impact factor: 9.941

9.  Thalidomide targets EGFL6 to inhibit EGFL6/PAX6 axis-driven angiogenesis in small bowel vascular malformation.

Authors:  Chao-Tao Tang; Qing-Wei Zhang; Shan Wu; Ming-Yu Tang; Qian Liang; Xiao-Lu Lin; Yun-Jie Gao; Zhi-Zheng Ge
Journal:  Cell Mol Life Sci       Date:  2020-02-01       Impact factor: 9.261

Review 10.  Cell Adhesion Molecules in Plasticity and Metastasis.

Authors:  Jessica A Smart; Julia E Oleksak; Edward J Hartsough
Journal:  Mol Cancer Res       Date:  2020-10-01       Impact factor: 6.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.